Morphologic and molecular prognostic markers in prostate cancer

Advances in Anatomic Pathology

Volumn 9, Issue 2, 2002, Pages 115-128

  Ross, Jeffrey S ^a,b   Sheehan, Christine E ^a   Dolen, Eric M ^a   Kallakury, Bhaskar V S ^a,c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Biomarker; Cell adhesion; Cell proliferation; DNA ploidy; Grade; HER 2 neu; Oncogene; Prognosis; Prostate cancer; Proteasome; Stage

Indexed keywords

CELL CYCLE PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

CANCER INVASION; CANCER STAGING; CARCINOMA; GENETICS; HUMAN; MALE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REVIEW;

CARCINOMA; CELL CYCLE PROTEINS; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036511983     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200203000-00003     Document Type: Review

References (171)

1. Boring CC, Squires TS, Tong T. Cancer statistics 1991. CA Cancer J Clin 1991;41:19-36.
2. Seidman H, Mushinski MH, Geib SK, et al. Probabilities of eventually developing or dying of cancer - United States, 1985. CA Cancer J Clin 1985;35:36-56. (Pubitemid 15127835)
3. Mettlin CJ, Murphy GP, Ho R, et al. The national cancer database report on longitudinal observations on prostate cancer. Cancer 1996;77:2162-6. (Pubitemid 26142065)
4. Lu-Yao GL, Greenberg R. Changes in prostate cancer incidence and treatment in USA. Lancet 1994;343:251-4. (Pubitemid 24039623)
5. Cookson MS. Prostate cancer: screening and early detection. Cancer Control 2001;8:133-40. (Pubitemid 32319371)
6. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000;11:167-70. (Pubitemid 30112017)
7. Montironi R, Mazzucchelli R, Marshall JR, et al. Prostate cancer prevention: review of target populations, pathologic biomarkers, and chemopreventive agents. J Clin Pathol 1999;52:793-803. (Pubitemid 29524938)
8. Christiano AP, Yoshida BA, Dubauskas Z, et al. Development of markers of prostate cancer metastasis. Review and perspective. Urol Oncol 2000;5:217-23.
9. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999;49:282-96. (Pubitemid 30142821)
10. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000. (Pubitemid 30602040)
11. Harding MA, Theodorescu D. Prostate tumor progression and prognosis. Interplay of tumor and host factors. Urol Oncol 2000;5:258-64.
12. Alers JC, Rochat J, Krijtenburg PJ, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest 2000;80:931-42. (Pubitemid 30421809)
13. Amanatullah DF, Reutens AT, Zafonte BT, et al. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci 2000;5:D372-90.
14. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 1994;74:104-14. (Pubitemid 24187618)
15. Hammond ME, Fitzgibbons PL, Compton CC, et al. College of American Pathologists Conference XXXV: solid tumor prognostic factors - which, how and so what? Arch Pathol Lab Med 2000;124:958-65.
16. Young RH, Srigley JR, Amin MB, et al. Tumors of the prostate gland, seminal vesicles, male urethra, and penis. In: Atlas of tumor pathology. 3rd series, fascicle 28. Washington, DC: Armed Forces Institute of Pathology, 2000:217-54.
17. Randolph TL, Amin MB, Ro JY, et al. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol 1997;10:612-29. (Pubitemid 27293503)
18. Kuhajda FP, Gipson T, Mendelsohn G. Papillary adenocarcinomas of the prostate. Cancer 1984;54:1328-32.
19. Cantrell BB, Leifer G, DeKlerk DP, et al. Papillary adenocarcinoma of the prostatic urethra with clear cell appearance. Cancer 1981;48:2661-7. (Pubitemid 12194257)
20. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical pathologic and ultrastructural findings. Am J Surg Pathol 1985;9:595-609. (Pubitemid 16220660)
21. Ro JY, Ayala AG, Wishnow KI, et al. Prostatic duct adenocarcinoma with endometrioid features: immunohistochemical and electron microscopic study. Semin Diagn Pathol 1988;5:301-11.
22. Epstein JI, Lieberman PH.Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol 1985;9:299-308. (Pubitemid 15037681)
23. Kuhajda FP, Mann RB. Adenoid cystic carcinoma of the prostate. A case report with immunoperoxidase staining for prostate-specific acid phosphatase and prostate-specific antigen. Am J Clin Pathol 1984;81:257-60. (Pubitemid 14150377)
24. Saito R, Davis BK, Ollapally EP. Adenosquamous carcinoma of the prostate. Hum Pathol 1984;15:87-9. (Pubitemid 14187574)
25. Moyana TN. Adenosquamous carcinoma of the prostate. Am J Surg Pathol 1987;11:403-7. (Pubitemid 17071221)
26. Devaney DM, Dorman A, Leader M. Adenosquamous carcinoma of the prostate, a case report. Hum Pathol 1991;22:1046-50.
27. Alline KM, Cohen MB. Signet-ring carcinoma of the prostate. Arch Pathol Lab Med 1992;116:99-102.
28. Ro JY, El-Naggar A, Ayala AG, et al. Signet-ring-cell carcinoma of the prostate. Electron-microscopic and immunohistochemical studies of 8 cases. Am J Surg Pathol 1988;12:453-60.
29. Ro JY, Tetu B, Ayala AG, et al. Small cell carcinoma of the prostate. Immunohistochemical and electron microscopic studies of 18 cases. Cancer 1987;59:977-82. (Pubitemid 17024655)
30. Johnson DE, Hogan JM, Ayala AG. Transitional cell carcinoma of the prostate. A clinical morphologic study. Cancer 1972;29:287-93.
31. Lauwers GY, Schevechuk M, Armenekas N, et al. Carcinosarcoma of the prostate. Am J Surg Pathol 1993;17:342-9. (Pubitemid 23096824)
32. Shannon RL, Ro JY, Grignon DJ, et al. Sarcomatoid carcinoma of the prostate, a clinical pathologic study of 12 patients. Cancer 1992;69:2676-82.
33. Thompson GJ, Albers DD, Broders AC. Unusual carcinomas involving the prostate gland. J Urol 1953;69:416-23.
34. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic pathology: the prostate. Philadelphia: Lea & Febiger, 1977:171-88.
35. Koch MO, Foster RS, Bell B, et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J Urol 2000;164(3 part 1):749-53. (Pubitemid 30637616)
36. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803. (Pubitemid 24229402)
37. Mills SE, Fowler JE. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer 1986;57:346-9. (Pubitemid 16212041)
38. Steinberg DM, Sauvageot J, Piantadosi S, et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J SurgPathol 1997;21:566-76. (Pubitemid 27213072)
39. Pan CC, Potter SR, Partin AW, et al. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000;24:563-9. (Pubitemid 30180750)
40. D'Amico AV, Wu Y, Chen MH, et al. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤7. Cancer 2001;89:1810-7.
41. McNeal JE, Villers AA, Redwine EA, et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;66:1225-33. (Pubitemid 20310665)
42. McNeal JE. Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread. Hum Pathol 1992;23:258-66.
43. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer. Cancer 1993;71:933-8.
44. Ravery V, Chastang C, Toublanc M, et al. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol 2000;37:449-55. (Pubitemid 30157807)
45. Montie JE. Staging of prostate cancer. Cancer 1995;75:1814-8.
46. Robinette MA, Robson CJ, Farrow GA, et al. Giant serial step sections of the prostate in assessment of the accuracy of clinical staging in patients with localized prostatic carcinoma [Abstract]. J Urol 1984;133(suppl):242A.
47. Epstein JI, Bizo VG, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93. (Pubitemid 23152669)
48. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B carcinoma of the prostate. Am J Surg Pathol 1993;17:336-41. (Pubitemid 23096823)
49. Rubin MA, Bassily N, Sanda M, et al. Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am J Surg Pathol 2000;24:183-9. (Pubitemid 30078706)
50. Ohori AM, Scardino PT, Lapin SL, et al. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 1993;17:1252-61. (Pubitemid 23344629)
51. Cheng L, Darson MF, Bergstralh EJ, et al. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999;86:1775-82. (Pubitemid 29513047)
52. Humphrey PA, Frazier HA, Vollmer RT, et al. Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. Cancer 1993;71:1821-7. (Pubitemid 23067399)
53. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy. Am J Surg Pathol 1996;20:286-92.
54. Herman CM, Wilcox GE, Kattan MW, et al. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol 2000;24:859-63. (Pubitemid 30366274)
55. Fowler J, Jr, Whitmore WF. The incidence and extent of pelvic lymph node metastasis in apparently localized prostatic cancer. Cancer 1981;47:2941-9.
56. Potter SR, Mangold LA, Shue MJ, et al. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer 2000;89:2577-86. (Pubitemid 32011602)
57. Okegawa T, Nutahara K, Higashihara E. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathologic stage T2 prostate cancer. Urology 2000;163:1183-8. (Pubitemid 30169387)
58. Foster CS, Abel PD. Clinical and molecular techniques for diagnosis and monitoring of prostate cancer. Hum Pathol 1992;23:395-401.
59. Isaacs JT. Molecular markers for prostate cancer metastasis. Am J Pathol 1997;150:1511-21.
60. Murphy GP, Barren RJ, Erickson SJ, et al. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer 1996;78:809-18. (Pubitemid 26268612)
61. Stege R, Grande M, Carlstrom K, et al. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000;6:160-5. (Pubitemid 30064989)
62. Chang SS, Reuter VE, Heston WD, et al. Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8. (Pubitemid 29316022)
63. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95:1735-40. (Pubitemid 28103463)
64. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-96. (Pubitemid 30160621)
65. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992;89:6319-23.
66. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Cancer 1993;71:2574-80.
67. Collembell M, Symmans F, Gil S, et al. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400. (Pubitemid 24058194)
68. Goel A, Abou-Ellela A, DeRose PB, et al. The prognostic significance of proliferation in prostate cancer. J Urol Pathol 1996;4:213-23.
69. Scalzo DA, Kallakury BVS, Gaddipati RV, et al. Cell proliferation rate by MIB-1 immunohistochemistry predicts post radiation recurrence of prostatic adenocarcinomas. Am J Clin Pathol 1998;109:163-8. (Pubitemid 28074365)
70. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol 1992;168:7-13.
71. Sadasivan R, Morgan R, Jennings S, et al. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 1993;150:126-31.
72. Henke RP, Kruger E, Ayhan N, et al. Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics. Virchow Arch Pathol Anat Histopathol 1993;422:61-6. (Pubitemid 23073666)
73. Furuya K, Akahura K, Masai M, et al. Changes in cell proliferation and apoptosis during local progression of prostate cancer. Anticancer Res 2000;20:1135-9. (Pubitemid 30240689)
74. Cheng L, Pisansky TM, Sebo TJ, et al. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res 1999;5:2820-3. (Pubitemid 29493957)
75. Drobnjak M, Osman I, Scher HI, et al. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000;6:1891-5. (Pubitemid 30305086)
76. Cheng L, Lloyd RV, Weaver AL, et al. The cell cycle inhibitors p21 WAF1 and p27 KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000;6:1896-9. (Pubitemid 30305087)
77. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-5. (Pubitemid 28106561)
78. Halvorsen OJ, Hostmark J, Haukaas S, et al. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 2000;88:416-24. (Pubitemid 30051828)
79. Kuczyk M, Hradil K, Schubach J, et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 1999;81:1052-8. (Pubitemid 29516151)
80. cdc2 and cyclin D1 protein expression in prostatic adenocarcinomas. Cancer 1997;80:753-63.
81. Ross JS, Nazeer T, Church K, et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 1993;72:3020-8. (Pubitemid 23335050)
82. Winkler HC, Rainwater LM, Myers RP, et al. Stage D1 prostatic carcinoma: significance of DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 1988;63:103-12. (Pubitemid 18064279)
83. Peters AJM, Miles BJ, Kubus JJ, et al. The prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma. Anal Quant Cytol Histol 1990;12:359-65. (Pubitemid 20357121)
84. Peters-Gee JM, Miles BJ, Cerny JC, et al. Prognostic significance of DNA quantification in stage D1 prostatic carcinoma with the use of image analysis. Cancer 1992;70:1159-65.
85. Foster CH, McLoughlin J, Bashir I, et al. Markers of the metastatic phenotype in prostate cancer. Hum Pathol 1992;23:381-94.
86. Montgomery BT, Nativ O, Blute M, et al. Stage B prostate adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Arch Surg 1990;125:327-31. (Pubitemid 20079074)
87. Ross JS, Figge H, Bui HX, et al. Prediction of pathologic stage and post prostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 1994;74:2811-8. (Pubitemid 24340549)
88. Ross JS, Sheehan CE, Ambros RA, et al. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am J Surg Pathol 1999;23:296-301. (Pubitemid 29117565)
89. Brinker DA, Ross JS, Tran TA, et al. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy and grade? J Urol 1999;162:2036-9.
90. Macouska JA, Trybus TM, Wojno KJ. 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer. Urology 2000;55:776-82.
91. Dong JT, Chen C, Stultz BG, et al. Deletion of 13q21 is associated with aggressive prostate cancers. Cancer Res 2000;60:3880-3. (Pubitemid 32204581)
92. Bowen C, Rubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-5.
93. Cadeddu JA, Pearson JD, Partin AW, et al. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology 1993;42:383-9. (Pubitemid 23314329)
94. Mohler JL, Metts JC, Zhang X-Z, et al. Nuclear morphometry in automatic biopsy and radical prostatectomy specimens of prostatic carcinoma. Anal Quant Cytol Histol 1994;16:415-20.
95. Mohler JL, Partin AW, Epstein JI, et al. Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer 1992;69:511-9.
96. Hurwitz MD, DeWeese TI, Zinreich ES, et al. Nuclear morphometry predicts disease-free survival for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. Int J Cancer 1999;22:594-7.
97. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9. (Pubitemid 24058195)
98. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 1993;24:220-6. (Pubitemid 23066603)
99. Siegal JA, Enyou YU, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545-51.
100. Silberman MA, Partin AW, Veltri RW, et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997;79:772-9. (Pubitemid 27076343)
101. Brawer MK, Deering RE, Brown M, et al. Predictors of pathologic stage in prostatic carcinoma. Cancer 1994;73:678-87.
102. Strohmeyer D, Rossing C, Strauss F, et al. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000;42:26-33. (Pubitemid 30004872)
103. De la Taille A, Katz AE, Bagiella E, et al. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. Am J Clin Pathol 2000;113:555-62. (Pubitemid 30217365)
104. Gettman MT, Bergstrahl EJ, Blute M. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density. Urology 1998;51:79-85. (Pubitemid 28092510)
105. Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results, and potential applications of color Doppler US scanning. Radiology 1993;186:509-13. (Pubitemid 23033881)
106. Newman JS, Bree RL, Rubin JM. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 1995;195:86-90.
107. Mohamed I, Peterson RO, Alexander AA, et al. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology 1997;50:906-12. (Pubitemid 28021109)
108. Louvar E, Littrup PJ, Goldstein A, et al. Correlation of color Doppler flow in the prostate with tissue microvascularity. Cancer 1998;83:135-40. (Pubitemid 28299639)
109. Partin AW, Getzenberg RH, Carmichael MJ, et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993;53:744-6. (Pubitemid 23077855)
110. Wise GJ, Marella VK, Talluri G, et al. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000;164:722-5. (Pubitemid 30637610)
111. Nakashima J, Machibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-6. (Pubitemid 30482107)
112. Ware JL. Prostate cancer progression. Implications of histopathology. Am J Pathol 1994;145:983-93. (Pubitemid 24345644)
113. Wikstrom P, Bergh A, Damber JE. Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol 2000;34:85-94. (Pubitemid 32046846)
114. Borre M, Newstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000;6:1882-90. (Pubitemid 30305085)
115. Kuniyasu H, Troncoso P, Johnson D, et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000;6:2295-308. (Pubitemid 30399196)
116. Bussemakers MJ, van-Moorselaar RJ, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52:2916-22.
117. Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 1993;12:29-37. (Pubitemid 23034089)
118. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
119. Bussemakers MJ, van Bokhoven A, Tomita K, et al. Complex cadherin expression in human prostate cancer cells. Int J Cancer 2000;85:446-50. (Pubitemid 30030421)
120. Ross JS, Figge HL, Bui HX, et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage and clinical outcome. Modern Pathol 1994;7:835-41.
121. Sandberg AA. Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 1992;23:368-80.
122. Harington KJ, Syrigos KN. The role of E-cadherin-catenin complex: more than an intercellular glue? Ann Surg Oncol 2000;7:783-8.
123. Kallakury BVS, Yang F, Figge J, et al. Decreased levels of CD44 protein and mRNA in prostate carcinoma: correlation with tumor grade and ploidy. Cancer 1996;78:1461-9. (Pubitemid 26317867)
124. Cohen MB, Griebling TL, Ahaghotu CA, et al. Cellular adhesion molecules in urologic malignancies. Am J Clin Pathol 1997;107:56-63. (Pubitemid 27104637)
125. Verkaik NS, van Steenbrugge GJ, van Weerden WM, et al. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest 2000;80:1291-8. (Pubitemid 30637069)
126. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999;52:189-96. (Pubitemid 29369203)
127. Pujol P, Maudelond T, Daures JP, et al. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993;71:2006-12. (Pubitemid 23068549)
128. Makar R, Mason A, Kittleson JM, et al. Immunohistochemical analysis of cathepsin D in prostate carcinoma. Mod Pathol 1994;7:747-51.
129. Ross JS, Nazeer T, Figge HL, et al. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Am J Clin Pathol 1995;104:36-41.
130. McCabe NP, Angwafo FF, Zaher A, et al. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep 2000;7:879-82.
131. Peehl DM. Oncogenes in prostate cancer. Cancer 1993;71:1159-64.
132. Wang YZ, Wong YC. Oncogenes and tumor suppressor genes in prostate cancer: a review. Urol Oncol 1997;3:41-6. (Pubitemid 27469234)
133. Neto GJ, Humphrey PA. Molecular biologic aspects of human prostatic carcinoma. Am J Clin Pathol 1994;102(suppl 1):S57-64. (Pubitemid 24345583)
134. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor and target of therapy. Oncologist 1998;3:237-52.
135. Ross JS, Sheehan C, Hayner-Buchan A, et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in-situ hybridization. Hum Pathol 1997;28:827-33. (Pubitemid 27298969)
136. Mark HF, Feldman D, Das S, et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999;66:170-8. (Pubitemid 29347506)
137. Kaltz-Wittmer C, Klenk U, Glaessgen A, et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 2000;80:1455-64.
138. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 199915;59:803-6.
139. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-25. (Pubitemid 32036922)
140. Ross JS, Kallakury BVS, Figge J. Pathology and molecular biology of prostate cancer. In: Rifkin MD, ed. Imaging of the prostate. New York: Lippincott Raven, 1997:179-90.
141. Kallakury BVS, Figge J, Ross JS, et al. Association of p53 immunoreactivity with high Gleason grade in prostatic adenocarcinoma. Hum Pathol 1994;25:92-7. (Pubitemid 24051831)
142. Navone N, Troncoso P, Pisters L, et al. p53 Protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69.
143. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999;162:2040-5.
144. Leibovich BC, Cheng L, Weaver AL, et al. Outcome prediction with p53 immunostaining in patients with locally advanced prostate cancer. J Urol 2000;153:1756-60. (Pubitemid 30366729)
145. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1, and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000;164:716-21. (Pubitemid 30637609)
146. Quinn DJ, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000;60:1585-94. (Pubitemid 30183429)
147. Visakorpi T, Kallioniemi O-P, Heikkinen A, et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1991;84:883-7.
148. Chi SG, deVere White RW, Meyers FJ, et al. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-33. (Pubitemid 24177307)
149. Kallakury BVS, Jennings TA, Ross JS, et al. Alteration of the p53 gene locus in benign hyperplastic prostatic epithelium associated with high grade prostatic adenocarcinoma. Diagn Mol Pathol 1994;3:227-32. (Pubitemid 24378936)
150. Meyers FJ, Chi SG, Fishman JR, et al. p53 mutations in benign prostatic hyperplasia. J Natl Cancer Inst 1993;85:1856-8. (Pubitemid 23333620)
151. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27 Kip1 expression. J Biol Chem 2000;275:24500-5. (Pubitemid 30626543)
152. McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-6. (Pubitemid 29418745)
153. Heidenreich B, Heidenreich A, Sesterhenn A, et al. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur Urol 2000;38:475-82.
154. Nguyen TT, Nguyen CT, Gonzales FA, et al. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers. Prostate 2000;43:233-42. (Pubitemid 30230460)
155. Dong JT, Rinker-Schaeffer CW, Ichikawa T, et al. Prostate cancer - biology of metastasis and its clinical implications. World J Urol 1996;14:182-9. (Pubitemid 126775160)
156. Brewster SF, Browne S, Brown KW. Somatic allelic loss at the DCC, APC, nm23 H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J Urol 1994;151:1073-7. (Pubitemid 24083517)
157. Bhangal G, Halford S, Wang J, et al. Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 2000;5:118-21. (Pubitemid 30182540)
158. Lee W-H, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the π-class glutathione-S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:1733-7.
159. Cookson MS, Reuter VE, Linkov I, et al. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol 1997;157:673-6. (Pubitemid 27026871)
160. Suh CI, Shanafelt T, May DJ, et al. Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol Cell Probes 2000;14:211-7.
161. Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res 2000;301:153-62. (Pubitemid 30459862)
162. Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995;146:1309-19.
163. Shabaik AS, Krajewski S, Burgan A, et al. bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol 1995;3:17-27.
164. Kallakury BVS, Figge J, Leibovich B, et al. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation. Mod Pathol 1996;9:41-7. (Pubitemid 26061951)
165. Wymenga LF, Wisman GB, Veenstra R, et al. Telomerase activity in needle biopsies from prostate cancer and benign prostates. Eur J Clin Invest 2000;30:330-5. (Pubitemid 30234862)
166. Wang Z, Ramin SA, Tsai C, et al. Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. Urol Oncol 2001;6:57-62. (Pubitemid 32106907)
167. Finlay JA, Day JR, Evans CL, et al. Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem 2001;47:1218-24. (Pubitemid 32579109)
168. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000;97:3850-5. (Pubitemid 30226050)
169. Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 1999;17:337-44. (Pubitemid 29331783)
170. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22. (Pubitemid 29269108)
171. Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719-28.